EFFICIENT REMOVAL OF SMALL MOLECULAR WEIGHT PROTEINS (SMWP) WITH A BROAD-SPECTRUM HEMOADSORPTION DEVICE (BetaSorbTM) COMBINED WITH HIGH-FLUX DIALYSIS (HFD) IN ESRD SUBJECTS:

Excessive mortality and morbidity in ESRD is associated with retention of SMWP and inflammatory cytokines not well removed by HFD. 12 ESRD subjects (8M, 4F, age 48±9) were enrolled in a study comparing 1 week of HFD (Fresenius F70NR) with 1 week HFD combined (CRx) with a new model of an adsorption column that removes SMWP from blood (BetaSorbTM, Renal Tech). SMWP (MW 11.8–21 kDa), beta2 microglobulin (β2m), angiogenin, leptin, retinol binding protein (rbp), and interleukin-18 (IL18), were measured pre- and post- treatment and % reduction calculated. Average β2m clearance (ACβ2m) and total removal (Tβ2m) were measured during 1 HFD and 1 CRx. Dialysis parameters were constant (BFR 300–400 ml/min, DFR 800 ml/min) and all measured plasma values were corrected for UF.TableClinically insignificant changes in leukocytes, platelets and albumin were observed with CRx. Significant reductions in SMWP relevant to ESRD were achieved. Addition of the BetaSorbTM offers potentially significant benefits not afforded by HFD.